CLOT MANAGEMENT DEVICES MARKET ANALYSIS

Market News

For instance, in April 2019, Tufts Medical Center in Boston and Eskenazi Health, a partner with the Indiana University School of Medicine, are developing a Mobile Active Compression (MAC) calf device for prevention of deep vein thrombosis. MAC is light-weight and portable device, which can be worn around limbs, as limbs have higher risk of deep vein thrombosis. Such innovations associated with clot management devices are expected to accelerate the global clot management devices market growth.

For instance, in May 2019, the U.S. Food and Drug Administration (FDA) approved Bashir Endovascular Catheter (BEC) and Bashir N-X endovascular catheter (BEC N-X) developed by a scientist from Temple University Hospital in Philadelphia, Pennsylvania and is being commercialized by Thrombolex, Inc. BEC received approval for its controlled infusion of fluids (thrombolytics) in peripheral vasculature and BEC N-X is being used for controlled infusion of fluids into pulmonary and peripheral vasculature.

Furthermore, activities such as collaborations, partnerships, merger, and acquisitions of the manufacturers are expected to drive the global clot management devices market growth. For instance, in September 2018, LeMaitre Vascular Corporation acquired vascular clot management business of Applied Medical Resources Corporation. The parties had undergone an agreement of transitional services, where Applied Medical Resources Corporation was supposed to manufacture its clot management product line for LeMaitre Vascular Corporation. This factor is expected to have a positive influence on the global clot management devices market growth over the forecast period.